Clinical trials are carefully designed research studies that answer specific questions about the safety and effectiveness of preventive techniques, medications, treatments, therapies or surgical techniques. Participation in a clinical trial is strictly voluntary.
Many studies that are developed and available are similar to treatments often referred to as the “gold standard.” Advancements in medicine may lead to improved outcomes through improved results, less discomfort, less time involved in treatment, lower cost, and/or improved safety. At Urology Associates, we are very selective about studies that we choose to offer to our patients. Please read further to see what is currently offered and contact our office with any questions.
Urology Associates is enrolling patients for clinical trials for benign prostatic hyperplasia (BPH), urologic cancers, stress incontinence, among others, in order to help our patients live longer, healthier lives.
Am I eligible?
Many studies have strict enrollment criteria. The list of inclusion and exclusion criteria are different for each study. Our office can easily assess whether a patient is eligible for a particular study.
Deciding whether or not to participate in a urology clinical trial is a very important choice that should be carefully considered and thoroughly discussed between a patient and his or her doctor.
VISTA – bladder cancer study
The purpose of this bladder cancer study is to assess the safety and tolerability of Vicinium monotherapy (administered via intravesical instillation) for the treatment of non-muscle invasive CIS and/or high-grade papillary disease of the bladder in subjects who failed previous treatment with Bacillus Calmette-Guerin (BCG).
- Male or non-pregnant, non-lactating female, age > 18 years
- Histologically confirmed high-grade non-muscle invasive bladder cancer – CIS, Ta or T1 papillary disease or some combination thereof following adequate BCG treatment and is unresponsive (refractory or relapsing)
- Evidence of urethral or upper tract transitional cell carcinoma (TCC) by biopsy or upper tract radiological imaging
- Subjects with hydronephrosis, except for those subjects in which this is longstanding (predates the diagnosis of CIS, Ta or T1 by more than 2 years) without evidence of tumor
- History of other primary malignancy (excluding squamous or basal cell skin cancers)
Xpert Study – bladder cancer assay studyThe purpose of this study is to establish the clinical performance characteristics of the Xpert Bladder Cancer Monitor on the GeneXpert Instrument Systems to detect the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.
- Male or female age 40 years or more
- Disease positive within 12 months
- Must provide at least 60mL of voided urine prior to SOC cystoscopy
- Patients who had an excision procedure within six weeks are ineligible
Bioness StimRouter study – overactive bladder (OAB)The purpose of this study is to assess the safety and efficacy of the StimRouter stimulation therapy in improving overactive bladder (OAB) symptoms when targeting the posterior tibial nerve.
- Male or female age 22 years or more
- Average urinary frequency of ≥10 daily voids with urgency
- Able to toilet self and maintain good personal hygiene
- Patient must have a body mass index (BMI) of less than or equal to 30
- Willing to discontinue any tricyclic antidepressant
- Treated with Botox or surgery in past 12 months
- Current or prior use of PTNS, SNS, pelvic floor muscle stimulation or biofeedback
Gelnique – pediatric detrusor overactivity studyThe purpose of this study is to evaluate the efficacy of daily treatment with oxybutynin chloride gel in pediatric patients with detrusor overactivity associated with a neurological condition who are using clean intermittent catheterization (CIC).
- Patient age 3 – 16 years
- Diagnosed with detrusor overactivity associated with a neurological condition
- Must be using CIC
- Patient-reported CIC use higher than 6 times within 24 hours
- Urinary tract anatomical abnormalities
- Have had surgical bladder augmentation within 1 year of study screening
TRUMPET study – Astellas metastatic castration-resistant prostate cancer (CRPC) registry
Collection of data from patients with metastatic castration-resistant prostate cancer (mCRPC) who are receiving their first approved, active course of anti-cancer treatment.Eligibility Criteria
- Male patient age > 18 years
- Confirmed diagnosis of CRPC, as defined by a minimum of two rising PSA levels measured at least 7 days apart, and serum testosterone level <73 nmol/L (50 ng/dL), or with new evidence of metastatic disease by investigating physician
- Initiating first active course of anti-cancer treatment for M0 CRPC or for M1 CRPC (regardless of prior M0 CRPC treatment) such as anti-androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. Patients may be enrolled within 45 days from the time of treatment initiation
- Patient is currently enrolled in any interventional clinic trial with a non-approved investigational agent for the primary disease of CRPC at study entry
- Patient is receiving concomitant treatment for other cancer (excluding basal cell carcinoma and treatment for hormone sensitive prostate cancer) within 6 months prior to enrollment